Core Viewpoint - The stock of CSPC Pharmaceutical Group (01093) has fallen over 10%, currently down 9.07% at HKD 9.72, with a trading volume of HKD 25.63 billion [1] Group 1: Strategic Partnership - CSPC Pharmaceutical Group announced a strategic cooperation and licensing agreement with AstraZeneca for the development of innovative long-acting peptide drugs [1] - The collaboration includes a clinical-ready long-acting GLP-1/GIP dual-target agonist project SYH2082 and three preclinical projects, with plans to explore four additional new projects [1] Group 2: Financial Implications - The licensing agreement sets a new record for overseas business development transactions in the GLP-1 sector [1] - CSPC will receive an upfront payment of USD 1.2 billion, with potential milestone payments for research reaching up to USD 3.5 billion and sales milestone payments up to USD 13.8 billion [1] - Additionally, CSPC is entitled to a sales commission based on the annual net sales of related products, with the total potential transaction amounting to USD 18.5 billion [1]
港股异动 | 石药集团(01093)倒跌逾10% 与阿斯利康签订多肽药大单 潜在交易总额最高达185亿美元